Induction therapy with twice-daily interferon-beta does not improve the therapeutic efficacy of consensus interferon monotherapy for chronic hepatitis C

Hidetsugu Saito, Shinichiro Tada, Hirotoshi Ebinuma, Hiromasa Ishii, Kazuo Kashiwazaki, Jiro Nishida, Takeshi Yoshida, Shigeyuki Zeki, Hideo Yoshida, Masahiro Yoshioka, Yasutaka Inagaki, Naoki Kumagai, Toshifumi Hibi

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)

Abstract

We examined therapeutic superiority of induction therapy with twice-daily IFN-β (3X2=6 million units/day) onto 6-months consensus interferon monotherapy for chronic hepatitis C. Patients were randomly assigned to monotherapy without (group I, n=16) and with induction therapy (group II, n=12). The mean age of group II was older than that of group I, and other baseline condition was not statistically significant. Sustained virological response (SVR) rates of group I and II were 81.3% (13/16) and 58.3% (7/12), respectively (p=0.365). SVR rates in patients with genotype 1b were 66.7% (4/6) and 0% (0/2, because of drop-out), and those with high viral load were 70% (7/10) and 75% (6/8) in group I and II, respectively (p=1.000). Drop-out rates during therapy were 6.3% (1/16) and 33.3% (4/12) in group I and II, respectively (p=0.176). Age less than 50 years was the only independent factor that was shown by multivariate logistic model analysis to be associated with a sustained virological response. Although randomization failed to produce and equal age distribution in the two groups in this study, our results suggest that induction therapy with twice-daily IFN-β has no beneficial effect on the efficacy of monotherapy with consensus interferon, probably because of the higher drop-out rates and incidence of adverse reactions with induction therapy.

Original languageEnglish
Pages (from-to)111-117
Number of pages7
JournalKeio Journal of Medicine
Volume55
Issue number3
DOIs
Publication statusPublished - 2006

Keywords

  • Consensus interferon
  • Induction therapy
  • Interferon-beta
  • Monotherapy

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Induction therapy with twice-daily interferon-beta does not improve the therapeutic efficacy of consensus interferon monotherapy for chronic hepatitis C'. Together they form a unique fingerprint.

Cite this